Podcasts about pharmd

In today's episode, Neil Iyengar, MD, moderated an OncLive Insights discussion about adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways. Dr Iyengar is an associate professor in the Department of Hematology and Medical Oncology and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; as well as director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia. He was joined by Heather Moore, CPP, PharmD, a clinical pharmacist practitioner at the Duke Cancer Center Breast Clinic in Durham, North Carolina; and Sarah Donahue, MPH, NP, a nurse practitioner at the University of California San Francisco Health.  In our exclusive discussion, the experts highlighted the importance of early and comprehensive testing (using both tissue and liquid biopsies) for genetic alterations to guide treatment decisions. They also noted strategies for managing diarrhea, including patient education on diet, proactive use of loperamide, and regular monitoring. They also explained that hyperglycemia management should hinge on prophylactic use of metformin or SGLT2 inhibitors, dietary restrictions, and frequent glucose monitoring. Their conversation on rash management included insights about prophylactic antihistamines, patient education on skin care, and involving dermatology for severe cases. Overall, the experts spotlighted the importance of multidisciplinary collaboration and proactive patient education when treating patients with breast cancer.

Dr. Emlah Tubuo shares how intentional living, whole-person care, and mindset are reshaping pharmacy, leadership, and personal wellbeing. Episode Summary In this episode of the YFP Podcast, Tim Ulbrich, PharmD sits down with Dr. Emlah Tubuo to explore what intentional living looks like in real life and in modern pharmacy practice. Emlah shares how Powell Pharmacy has evolved beyond dispensing into whole-person care, including biomarker testing, hormone optimization, and integrated wellness services. They discuss resilience, mindset, and how pharmacists can reclaim purpose by meeting patients where they are, while also addressing burnout, fear, and the power of being fully present. Whether you are a pharmacist, entrepreneur, or someone seeking a more aligned and intentional life, this conversation offers both inspiration and practical insight. What you'll learn in this episode: How intentional living can transform pharmacy practice and patient care Why whole-person care goes beyond prescriptions and lab values alone Practical ways pharmacists can integrate biomarkers, hormones, and wellness initiatives How mindset, presence, and resilience reduce burnout and improve impact What it means to redefine success through service, alignment, and purpose Mentioned on the Show Powell Pharmacy Journeys Lab Testing for Pharmacists Pharmacist Fullscript Account Setup Lunch and Learn Supplement Knowledge Discuss Dietary Supplements With Confidence Intentional Living Newsletter Emlah Naturals Intentional Living Podcast Emlah Tubuo - LinkedIn Emlah Tubuo - Instagram

In this powerful episode of MaternalRx on the Pharmacy Podcast Network, host Danielle Plummer, PharmD, speaks with pharmacist Willie Bawarski and his wife, Olivia, about their deeply personal journey through infertility, IVF treatment, foster care, and adoption. Willie and Olivia share the emotional, physical, and financial realities of trying to conceive, navigating fertility treatments, and facing the grief that often accompanies infertility. When their path to parenthood changed, they chose to open their hearts and home through foster care and adoption, ultimately building a beautiful family in ways they never expected. This conversation highlights the critical role pharmacists and healthcare professionals play in supporting patients experiencing infertility and those considering foster care or adoption. Listeners will gain practical insight into using compassionate language, empathy, and trauma-informed care to support individuals and couples during some of the most vulnerable seasons of their lives. Whether you are facing infertility, exploring IVF, considering adoption, working within maternal health, or caring for patients on these journeys, this episode offers hope, validation, and a reminder that family is defined by love, not biology.

This INSIGHTS episode revisits a core topic from Neurocritical Care ON CALL®, originally released in July 2023.  Listen to the second episode of the NCS INSIGHTS series on status epilepticus (part 2 of 2). The INSIGHTS series is hosted by Casey Albin, MD, and Salia Farrokh, PharmD, and covers topics from Neurocritical Care ON CALL®, the only up-to-date, comprehensive resource dedicated exclusively to the practice of neurocritical care. Learn more about ON CALL®. This episode is sponsored by Ceribell. Time is brain when it comes to seizures. Ceribell point-of-care EEG empowers the bedside team to detect or rule out seizure activity in minutes. To learn more, visit ceribell.com. The NCS Podcast is the official podcast of the Neurocritical Care Society. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

Could low cortisol be the hidden reason behind chronic fatigue, poor stress tolerance, sleep disruptions, or mood changes? Cortisol is often misunderstood as just a “stress hormone,” but it plays a critical role in regulating energy levels, emotional resilience, inflammation, and the body's natural sleep-wake cycle. When cortisol production becomes depleted due to prolonged stress, illness, or trauma, the body may struggle to function optimally, leading to symptoms commonly associated with adrenal insufficiency. Join us today as Bryana Gregory, PharmD, RPh, Pharmacist and Physician Liaison at Physicians Preference Pharmacy, explains how compounded oral cortisol can be used as a personalized hormone replacement option to support adrenal function. She walks through how cortisol naturally follows a diurnal rhythm, why low levels can disrupt sleep and energy, and how carefully dosed replacement may help restore balance. The discussion also highlights how compounded formulations allow for individualized dosing, cleaner ingredients, and delivery methods that better mimic the body's natural cortisol patterns. Listeners will gain insight into who may benefit from cortisol replacement, how it differs from adrenal supplements, and why more is not always better when it comes to hormone therapy. This episode emphasizes the importance of working closely with a knowledgeable physician to address symptoms, monitor response, and create a customized approach that supports long-term wellness, resilience, and overall quality of life. To learn more, visit www.PhysiciansPreferenceRX.com or call 281-828-9088. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

Could medications originally designed for diabetes actually help treat addiction, eating disorders, and the biology of cravings?In this part 2 of 2-part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to dig deeper into the science, myths, and emerging uses of GLP-1 agonists. Dr. Wharton explains that these medications don't simply reduce appetite, they calm what he calls “food noise,” the constant mental pull toward eating that many people with obesity experience. This neurological effect has opened the door to exciting possibilities: early research suggests GLP-1 drugs may also reduce cravings for alcohol and other addictive behaviors.  Dr. Wharton also clarifies the confusing world of brand names. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are tirzepatide. The differences are largely about FDA indications and insurance coverage, not completely different medications.The episode tackles common fears patients and clinicians hear every day. Do these medications cause eating disorders? No, in fact, they may help treat them. Are the side effects dangerous? Usually not, and most are manageable with proper dosing. Is “Ozempic face” real? It's simply normal fat loss, not a drug-specific problem. Most importantly, Dr. Wharton reinforces a compassionate, evidence-based message: obesity is a chronic, biological disease, and GLP-1 medications are tools to treat it, just like medications for blood pressure or diabetes.Three Actionable TakeawaysGLP-1 Medications Affect the Brain as Much as the Stomach: These drugs reduce “food noise” and cravings, helping patients regain control over eating behaviors. Their impact is neurological, not simply about willpower or restriction.Side Effects Are Real—but Usually Manageable: Nausea, constipation, and GI symptoms are the most common issues, especially early on. Starting low and increasing doses slowly makes treatment far more tolerable.Treatment Decisions Should Be Individualized:  Not every patient must stay on these medications forever. Conversations about duration, goals, and expectations should be collaborative and tailored to each person.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

DESCRIPTIONIn this episode of the FIT40 Podcast, I'm joined by Dr. Ashley Dwyer to break down the new nutrition guidelines and why they're confusing so many women over 40. We talk protein needs, fiber intake, gut health, saturated fat, carbs, and the rise of nutrition misinformation online. Ashley explains what actually matters for fat loss, heart health, and digestion after 40, why extreme diets backfire, and how to build a realistic, evidence-based approach that fits busy real life. If you're tired of conflicting advice and want clarity without extremes, this episode is a must-listen.HOW TO FIND DR DWYERInstagram: https://www.instagram.com/dr.dwyerFIT40 LINKS✅ Feeling low on energy and out of shape but short on time?

John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information in Vizient's Center for Pharmacy Practice Excellence and Vizient's vaccine subject matter expert, joins host Stacy Lauderdale to discuss key updates to the CDC's childhood Immunization schedule and what they mean for practice.   Guest speaker:     John Schoen, PharmD, BCPS   Senior Clinical Manager of Evidence-Based Medicine and Drug Information    Vizient Center for Pharmacy Practice Excellence     Host:   Stacy Lauderdale, PharmD, BCPS   Associate Vice President  Vizient Center for Pharmacy Practice Excellence   Verified Rx Host    00:00 — Introduction Announcer welcomes listeners to Verified Rx, produced by the Vizient Center for Pharmacy Practice Excellence. 00:14 — Episode Overview Host Stacy Lauderdale introduces the topic: updates to the CDC's U.S. Childhood Immunization Schedule, revised January 20, 2026. Goal of the episode: explain what changed, what didn't, and what it means in practice for providers, pharmacists, and families. Guest: John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information at Vizient and vaccine subject matter expert. 01:16 — What Changed in the CDC Immunization Schedule CDC reorganized the schedule into three recommendation categories. Vaccines were reclassified, not removed. Number of diseases covered under “routine” recommendations decreased from 17 to 11 due to recategorization. 01:50 — Stated Rationale Behind the Changes Rationale provided in executive summary of scientific assessment. The supporting scientific assessment is available online and referenced for transparency (link in resources below). 03:19 — Were Any Vaccines Removed? No vaccines were removed from the CDC schedule. Some vaccines were shifted into different recommendation categories. 03:40 — Category 1: Routine Childhood Vaccinations Vaccines still routinely recommended for all children include: MMR (measles, mumps, rubella) Polio Tdap / DTaP Hib (Haemophilus influenzae type B) Pneumococcal HPV Varicella (chickenpox) 04:27 — Category 2: Vaccines for High-Risk Populations Vaccines recommended for children who meet specific high-risk criteria: RSV monoclonal antibodies (mAb) Hepatitis A Hepatitis B Quadrivalent meningococcal Meningococcal group B Dengue 05:19 — What Changed vs. Stayed the Same Hepatitis A, Hepatitis B, and quadrivalent meningococcal moved from routine to high-risk RSV mAb recommendations are effectively unchanged, as high-risk infants are defined as those born to mothers who did not receive the maternal RSV vaccine. Dengue remains risk-based. Meningococcal group B remains a mix of risk-based and shared clinical decision-making. 06:31 — Category 3: Shared Clinical Decision Making (SCDM) Defined by ACIP as an individualized decision made jointly by provider and parent/guardian. Allows vaccination when risk-based criteria are not met but benefit is still considered. 06:52 — Vaccines Under SCDM Vaccines now include: Influenza COVID-19 Rotavirus Hepatitis A Hepatitis B Quadrivalent meningococcal Meningococcal group B 08:05 — What's New in SCDM Influenza and rotavirus moved from routine to SCDM. Hepatitis A, hepatitis B, and quadrivalent meningococcal also shifted. COVID-19 moved to SCDM in September 2025 for individuals ≥6 months. 08:28 — Insurance Coverage Implications No expected changes in coverage. Vaccines recommended by CDC as of December 31, 2025 remain: Covered without cost-sharing under Affordable Care Act (ACA) plans. Covered by Medicaid, Children's Health Insurance Program (CHIP), and Vaccines for Children (VFC) program. 09:14 — Impact on Pharmacy Vaccine Access Pharmacists are considered healthcare providers under CDC SCDM definitions. Authority to administer vaccines primarily determined by state laws. Standing orders, protocols, and collaborative practice agreements may need to be updated, as applicable, to address language related to ‘routine' immunizations for children. 10:27 — Recommendations for Providers & Organizations For providers: Become familiar with schedule changes. Be prepared for patient and parent education. Recognize differences between CDC and other professional guidelines. For organizations: Review EHR documentation and order sets. Consult local state regulations to ensure compliance with vaccine administration practices. Review standing orders/protocols and collaborative practice agreements to determine if revisions are needed. Monitor vaccine utilization and adjust inventory accordingly. 11:24 — Resources & Closing Additional CDC and Vizient resources will be linked in the show notes. Announcer closes with subscription and feedback reminder. Links | Resources:    Additional resources HHS press release on changes to childhood immunizations schedule Assessment of US childhood and adolescent immunization schedule HHS fact sheet: CDC childhood immunization schedule Revised CDC child and adolescent immunization schedule ACIP shared clinical decision-making recommendations   Vizient resource Minute Market Insight   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed  

On this episode, we define hypothyroidism and hyperthyroidism and describe their clinical presentations, etiologies, and underlying pathophysiology. We also evaluate current guidelines and evidence-based treatment strategies for the management of hypothyroidism and hyperthyroidism. Then, we compare and contrast the efficacy, safety profiles, and appropriate use of therapies for thyroid disorders, including hormone replacement, antithyroid medications, radioactive iodine, and monitoring strategies.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

In this episode, Todd Karpinski, PharmD, MS, FASHP, FACHE, System Vice President and Chief Pharmacy Officer at WVU Medicine, joins the podcast to discuss the evolving pharmacy landscape. He shares perspectives on ongoing challenges with retail pharmacy reimbursements, addressing staffing shortages, and how strategic partnerships can support sustainable growth and strengthen pharmacy operations across the health system.

On this episode host Fred Goldstein invites Angela Luong, PharmD, Senior Clinical Consultant at Pharmaceutical Strategies Group in this last installment of our rare disease series. Our discussion focuses on the burden of sickle cell disease, chronic pain management, limited treatment options, and the implications for managed care programs, including the use of data and care coordination to improve patient outcomes. This activity is supported by an independent medical education grant from Agios Pharmaceuticals, Inc. AMCP offers CPE for this podcast through December 31, 2026. For additional information and to claim credit, please visit: The Power of Partnership: Bridging Patients and Payers in Sickle Cell Disease Management. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In this episode, Roya Tran, PharmD, MS, 340B ACE, Associate Chief Pharmacy Officer for Pharmacy Finance and Supply Chain at Duke Health, joins the podcast to discuss her experience with the 340B program and how it supports access to care. She shares perspectives on expanding the ambulatory pharmacy space, identifying growth opportunities, and improving access to pharmaceutical care through strategic finance and supply chain alignment.

In this episode, Bethanie Stein, PharmD, Segment President of Pharmacy at Humana, discusses how employers are approaching GLP-1 coverage and why partnerships with manufacturers like Eli Lilly and Novo Nordisk matter now. She shares how CenterWell Pharmacy is using transparency, clinical oversight, and adherence focused models to expand access while managing costs.

In this episode, Justin L. Vesser, PharmD, MS, Director of Ambulatory Pharmacy at UVA Health, shares how his team expanded clinical pharmacy services, improved medication access, and grew retail operations to better serve patients across Virginia. He also discusses navigating reimbursement pressures, regulatory headwinds, and leading through change by anchoring pharmacy teams in a clear mission.

In this episode, Edith Okolo, PharmD, RPh, Director of Pharmacy at Cedar Crest Hospital, joins the podcast to discuss pharmacy priorities heading into 2026, with patient safety at the forefront. She shares insights on improving workflow efficiency, addressing medication affordability—particularly long-acting injectables—and navigating ongoing medication shortages and broader industry challenges.

This INSIGHTS episode revisits a core topic from Neurocritical Care ON CALL®, originally released in July 2023.  Listen to the first episode of the NCS INSIGHTS series on status epilepticus (part 1 of 2). The INSIGHTS series is hosted by Casey Albin, MD, and Salia Farrokh, PharmD, and covers topics from Neurocritical Care ON CALL®, the only up-to-date, comprehensive resource dedicated exclusively to the practice of neurocritical care. Learn more about ON CALL®. This episode is sponsored by Ceribell. Time is brain when it comes to seizures. Ceribell point-of-care EEG empowers the bedside team to detect or rule out seizure activity in minutes. To learn more, visit ceribell.com. The NCS Podcast is the official podcast of the Neurocritical Care Society. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

I'm celebrating 6 years in podcasting today!

In this episode, Nick Gazda, PharmD, MS, BCPS, CSP, Director of Pharmacy Oncology and Infusion at Cone Health, discusses how standardized infusion services, centralized medication access, and technology integration have improved patient care and operational efficiency. He also shares strategies for navigating financial and regulatory headwinds while pursuing growth and value-based opportunities in 2026.

Send us a textSchedule an Rx AssessmentAI in pharmacy isn't about prompts, dashboards, or “nice-to-have” tools, it's about execution.In this episode of the Bottom Line Pharmacy Podcast, Austin Murray sits down with Natalie Park, PharmD, co-founder and CEO of Pharmesol, to break down what AI agents actually are and why they represent a major shift in how pharmacies operate, scale, and compete.We uncover: What an AI agent really isHow AI agents can execute workflowsHow automation is driving real revenue growthWhere pharmacies are seeing the biggest early winsAnd more!More About Our Guest:Dr. Natalie Park, Pharm.D. is a pharmacist, entrepreneur, and health technology innovator who exemplifies how a pharmacy degree can become a launchpad for transformative impact.A proud graduate of The Ohio State University College of Pharmacy, Natalie brings a bold, initiative-driven mindset to everything she does embracing challenges, valuing diverse experiences, and firmly believing that practice, not theory alone, drives meaningful change.Fueled by a passion for digital health, innovation, and health policy, Natalie is the founder and CEO of Pharmesol, an AI-powered pharmacy assistant designed to strengthen connections between practitioners and patients while improving access to care. Her interests span comparative effectiveness research, health technology assessment, and healthcare innovation, all with a focus on practical, real-world application.Natalie's journey into pharmacy is deeply personal. After moving to the U.S. as a teenager, she struggled to navigate the healthcare system. When she experienced an allergic reaction for the first time, she turned to a pharmacy—simply because she didn't know where else to go. That moment shaped her purpose and inspired her to pursue pharmacy as a pathway to accessible, patient-centered care.Today, as a technology CEO serving pharmacies, Natalie's work blends strategy, customer engagement, and problem-solving. She partners closely with pharmacy leaders to understand their needs, guides product innovation with intention, and keeps her team focused on delivering meaningful value. Her career is a testament to lifelong learning—not as something additive, but transformative—and to the idea that pharmacy isn't just a profession, but a platform for limitless possibilities.Stay connected with Natalie and Pharmesol:Natalie's LinkedInPharmesol WebsitePharmesol LinkedInStay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic:Podcast - Driving Independent Pharmacy Profitability in 2026Podcast – The Startup Compounding Pharmacy PlaybookPodcast – Inside the Fight for Compounding: Advocacy, Growth, and Regulation

The American Diabetes Association's 2026 Standards of Care in Diabetes are here! Let's talk about what's changed and how to better care for our older adults living with diabetes. 2026 Standards of Care in Diabetes:  https://diabetesjournals.org/care/issue/49/Supplement_1 Tamara Ruggles, PharmD, BCGP, FASCP:  www.linkedin.com/in/tamara-ruggles-491882251 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES:  https://www.linkedin.com/in/diana-isaacs-pharmd-bcps-bcacp-bc-adm-cdces-45803426/  

Are GLP-1 medications truly revolutionizing medicine—or are we just seeing the latest healthcare hype cycle?In this part 1 of 2- part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to explore the real story behind GLP-1 agonists, how they were discovered, how they work, and why they suddenly became cultural blockbusters. Dr. Wharton explains that while the public sees these drugs as new, clinicians in diabetes care have been using them for over a decade. Originally developed to treat type 2 diabetes, GLP-1 medications revealed an unexpected benefit: meaningful weight loss. What began as a “sleeper drug” for glucose control became a global phenomenon once their impact on appetite and cravings was understood.A major theme of the discussion is the concept of “food noise”—the relentless mental pull toward food that many patients experience. Dr. Wharton describes how this biological drive makes long-term weight loss extraordinarily difficult and why willpower alone is rarely enough. GLP-1 medications work by quieting this food noise, helping patients regain control over their eating behaviors.The conversation also tackles tough questions clinicians and patients ask every day:Why do people need to stay on these medications long-term? Why do patients with diabetes lose less weight than those without? Is obesity truly a disease, and how should doctors talk about it? Are the benefits due to the drug itself or simply the weight loss? Dr. Wharton breaks down the biology of GLP-1 hormones, their role in insulin regulation and appetite control, and why these drugs have been such rare “unicorns” in medicine, highly effective with relatively few side effects.This episode sets the stage for Part 2, where they will dive deeper into myths, side effects, and practical prescribing guidance.Three Actionable TakeawaysObesity Is a Biological Disease, Not a Willpower Problem: Food noise and cravings are driven by hormones and brain chemistry. GLP-1 medications treat these biological mechanisms, not a character flaw.Long-Term Treatment Is Often Necessary: Just like medications for blood pressure or cholesterol, GLP-1 drugs address a chronic condition. Stopping treatment usually means the underlying biology—and weight—returns.Language Matters in Patient Care: Clinicians should approach weight with empathy and humility. Inviting patients into a respectful conversation about options is far more effective than blaming or shaming.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We're stepping out of our Medicine on the Go series for a rapid-response episode on something hitting all of us hard right now: **influenza**. A lively debate among our colleagues sparked this conversation—especially around a newer flu antiviral, baloxavir (Xofluza). Who's using it? When does it make sense? How much does it cost patients? And how does it really compare to the longtime staple oseltamivir (Tamiflu)? The questions came fast, the opinions were strong, and we knew it was time to dig in. With flu season in full swing, this episode is all about practical decision-making at the bedside. Back to Basics: How Flu Antivirals Work To help break it all down, we welcome back our trusted ED pharmacist, Haley Burhans. We begin with a quick review of how influenza antivirals have evolved. , approved in 1999, was the first widely used antiviral and works by blocking the neuraminidase enzyme. Over time, concerns about resistance led to the development of newer options. That brings us to baloxavir (Xofluza), approved in 2018. Xofluza works differently by stopping viral replication earlier in the virus life cycle. While both medications aim to shorten illness and reduce complications, they differ in how they work, how they are dosed, and which patients benefit most. Who Should Get What—and When? Next, we focus on real-world ED decision-making. Who should receive Tamiflu, and who is a good candidate for Xofluza? We review use in children, pregnant patients, hospitalized patients with severe or worsening illness, immunocompromised patients, and those at higher risk due to conditions like asthma, lung disease, diabetes, heart disease, obesity, or older age. Timing is critical. Both medications work best when started within 48 hours of symptom onset. However, oseltamivir is still recommended even after that window for patients who are hospitalized or severely ill. We also discuss when antivirals can be used for post-exposure prpphylaxis. What Does the Evidence Say? We then take a closer look at the data behind antiviral treatment. Both Tamiflu and Xofluza shorten the time to symptom improvement. Observational studies suggest oseltamivir may reduce hospital length of stay and in-hospital death in adults and shorten hospital stays in children. Trial data also suggest baloxavir may be more effective against influenza B. We compare dosing strategies—five days of twice-daily Tamiflu versus a single-dose Xofluza—and review side effects and pediatric considerations. Real-World Barriers: Access and Cost Finally, we tackle the practical issues clinicians face every day. Tamiflu is widely available and familiar to most providers. Xofluza, on the other hand, often requires prior authorization and may be harder for patients to obtain. We discuss insurance barriers, out-of-pocket costs, manufacturer coupons, and situations where Xofluza may or may not be a realistic option. Take-Home Message This episode is a practical, evidence-based conversation designed to help emergency clinicians make confident decisions during flu season. Whether you're treating a high-risk patient, considering a single-dose option for uncomplicated flu, or simply trying to stay current, this discussion delivers clear, useful guidance you can use on your next shift! What's your go to flu treatment? What other medications would you like to learn more about? Hit us up on social media @empulsepodcast or at ucdavisem.com Hosts: Dr. Julia Magaña, Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Professor of Emergency Medicine at UC Davis Guests: Haley Burhans, PharmD, Emergency Medicine Clinical Pharmacist at UC Davis Resources: CDC: Influenza Antiviral Medications: Summary for Clinicians AAP: Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement ACEP Influenza Resources and Updates **** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

What if financial success isn't about saving more, but aligning money with the life you want today? Episode Summary After years of doing "everything right" financially, many pharmacists reach a surprising crossroads: retirement feels on track, but something still feels off. In this solo episode, Tim Ulbrich, PharmD reflects on a counterintuitive decision he has made over the past five years by intentionally not maxing out traditional retirement accounts, and the deeper question that choice surfaced: what are you optimizing for right now? This conversation explores the tension between financial efficiency and life alignment, the concept of "enough," and why financial planning in mid-career is less about winning spreadsheets and more about finding a way to live your rich life today while preparing for the future. What you'll learn in this episode: Why "on track" financially doesn't always feel satisfying  The difference between accumulating wealth and being truly retirement-ready The hidden risk of always optimizing your financial plan for a future state at the expense of today Why "enough" is a decision, not just a number

In this month's podcast episode, The Standards, hosts Neil Skolnik, MD, and Sara Wettergreen, PharmD, BCACP, BC-ADM, explain the Standards of Care in Diabetes from the American Diabetes Association® in clear, plain terms. This conversation is designed to help you better understand the guidance that shapes diabetes and obesity care. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!   Additional resources: Access the Standards of Care in Diabetes—2026 Access sections 1-3 of the Standards of Care in Overweight and Obesity Access Your Rights and Care Standards: A Guide for People with Type 2 Diabetes          

Send us a textSchedule an Rx AssessmentLevi is hiring! Interested in working for a pharmacy that runs on structure, relationships, and a high-performance Med Sync model (not “rat race” retail)? Click hereIf you really want to maximize your Med Sync program, you need to shift your mindset from "Med Sync is a “program” to "Med Sync is our culture and a competitive advantage."In this episode of the Bottom Line Pharmacy Podcast, Scotty Sykes, CPA, CFP®, Bonnie Bond, CPA, MBA, and Austin Murray sit down with Dr. Levi Ellison, PharmD, Owner of Ellison Family Pharmacy to discuss his Med Sync operation, how it's driving 42 inventory turns and creating a smoother, calmer experience for patients and staff.We break down:Med Sync as opt-out, not opt-inHow Med Sync creates financial leverageWhy Levi believes Med Sync benefits everyoneThe Med Sync workflow driving above average inventory turnsAnd more!More About Our Guest:Dr. Levi Ellison, PharmD is the owner of Ellison Family Pharmacy. An independent pharmacy located in Mena Arkansas.Levi's roots run deep in Polk County with his family going back six or more generations on both sides. Both Levi graduated with a Doctor of Pharmacy degree in 2018 from UAMS College of Pharmacy in Little Rock, AR. Levi serves as the pharmacist in charge of Ellison Family Pharmacy and Jessica works part time as a pharmacist.Levi is a very active member of Salem Baptist Church located in the community of Nunley just outside Mena. He is also a member of the Arkansas Pharmacists Association and the National Community Pharmacists Association. In his limited free time he enjoys spending time with wife Jessica hiking and with their children.Stay connected with Levi and Ellison Family Pharmacy: Levi's LinkedInEllison Rx WebsiteEllison Rx Facebook Stay connected with us: FacebookYouTube LinkedInInstagramMore resources on this topic: Podcast - Driving Independent Pharmacy Profitability in 2026Podcast – The Startup Compounding Pharmacy PlaybookPodcast – Inside the Fight for Compounding: Advocacy, Growth, and Regulation

On this episode, we discuss community-acquired pneumonia (CAP) and its clinical presentation, common etiologies, and underlying pathophysiology. We review current guidelines and evidence-based treatment recommendations for managing CAP, including diagnostic criteria, severity assessment tools, and appropriate antimicrobial selection. We also compare and contrast the efficacy, safety considerations, and appropriate use of antimicrobial therapies, supportive care measures, and monitoring strategies in the treatment of CAP. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristina O'Connor, PharmD, BCPS, BCIDPClinical Pharmacy ManagerMayo Clinic Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence.2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education.Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-038-H01-PInitial release date: 1/12/2026Expiration date: 1/12/2027Additional CPE details can be found here.

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristina O'Connor, PharmD, BCPS, BCIDPClinical Pharmacy ManagerMayo ClinicPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence.2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education.Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-038-H01-PInitial release date: 1/12/2026Expiration date: 1/12/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

In this episode, Joshua Weber, PharmD, MBA-HCM, CSP, BCMTMS, 340B ACE, Senior Director, St. Luke's Health System, highlights the organization's future-ready pharmacy transformation, including paperless workflows, AI-enabled prior authorizations, EHR-integrated benefits investigations, and expanded specialty drug access for 5,000 more patients.

In this episode, Thomas Carey, PharmD, Senior Director, Pharmacy Services, UW Northern Illinois, shares how the organization elevated its Med to Bed discharge program using multidisciplinary coordination, driving a nearly 30% reduction in 30-day readmissions. He also discusses agility in 340B compliance, leveraging learners, and the future of pharmacy growth through technology, automation, and workforce investment.

In this episode, Liz Unruh is joined by Kelly Eagan, PharmD, BCPS, BCACP, CDCES, the lead clinical pharmacist at Riverside's Cardiology Pharmacotherapy Clinic (CPC). Discover how clinical pharmacists play a crucial role in patient care management, help manage chronic conditions, and optimize medication therapy to ensure best outcomes for patients. Tune in to understand the unique value they bring to the healthcare team!

Send us a textSchedule an Rx AssessmentPeptides, telemedicine, speed-to-market. Independent pharmacies have real profitability levers in 2026 but the winners will be the ones who can move fast and stay compliant.In this episode, Scotty Sykes, CPA, CFP, Bonnie Bond, CPA, MBA, and Austin Murray sit down with Dr. Nicolette Mathey, PharmD, CEO of Atrium24 to unpack what's changing right now in the compounding and wellness economy.We cover:Why peptides are exploding in demandWhat to know about BPC-157 and why many think FDA movement could be comingHow pharmacies can use telemedicine to keep patients from being captured by big direct-to-consumer platformsWhere compounding pharmacies are still thrivingSpeed to market without reckless riskMore About Our Guest:Dr. Nicolette Mathey started her career at Walgreens at age 16 and earned her PharmD from the University of Florida in 2010. After pioneering a successful Bedside Delivery program at BayCare Health Systems, she became the Director of Clinical Services at Pharmacy Development Services. There, she co-developed the Clinical Services Profit Ignitor and played a pivotal role in early data analytics. In 2017, Nicolette acquired Palm Harbor Pharmacy, transforming it from a contracts-only establishment in a Heat Zone to a thriving hub. She revamped its identity, introducing robust digital marketing, a multi-rep sales system, compounding, immunizations, NABP accreditation, Test & Treat, Pharmacogenomic (PGX) Testing, and more. In 2019, Nicolette founded ATRIUM24, initially offering business consulting to pharmacies. Focused on developing software to automate data analytics and launch Dotti, the industry's first CRM sales system tailored for pharmacies, she sold Palm Harbor Pharmacy to another independent owner in October 2023. With the official launch of Dotti in January 2024, Dr. Mathey continues to innovate, aiding pharmacies in maximizing their data for profitability and growth. Through ATRIUM24 and Dotti, she and her team “connect the dots” for sales and marketing initiatives, empowering pharmacies with cutting-edge tools. Stay connected with Nicolette, Atrium24, and Dotti: Nicolette's LinkedInAtrium24 WebsiteAtrium24 FacebookAtrium24 LinkedInStay connected with us: FacebookYouTube LinkedInInstagram More resources on this topic: Podcast – The Startup Compounding Pharmacy PlaybookPodcast – Inside the Fight for Compounding: Advocacy, Growth, and Regulation

Robert Mancini, PharmD, BCOP, FHOPA is the current President of HOPA and the Oncology Pharmacy Program Coordinator and PGY2 Oncology Residency Program Director at St Luke's Cancer Institute in Boise, ID. Dr. Mancini talks through his priorities for HOPA this year and the latest in the world of oncology!

On this episode Fred Goldstein invites Steve Kheloussi, PharmD, MBA, FAMCP, Principal Consultant at Kheloussi Consulting, LLC, in the first installment of our four-part series on rare diseases. We discuss a practical overview of Duchenne muscular dystrophy (DMD), the current treatment landscape, and the evidence gaps that complicate payer decision-making. We also touch on the importance of what patients and caregivers need to maintain function, reduce fatigue, and navigate the significant emotional and practical burdens of care. This podcast is supported by an independent medical education grant from ITF Therapeutics. AMCP offers CPE for this podcast through December 31, 2026. For additional information and to claim credit, please visit:  ⁠The Power of Partnership: Bridging Patients and Payers in Duchenne Muscular Dystrophy Management⁠. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

On this episode of Danatech Talks–a special series from The Huddle– Paola Acevedo, PharmD, CDCES, walks through how to simplify the process of prescribing diabetes technology. Paola discusses common pain points both clients and prescribers may face related to documentation, coverage and affordability, and accessibility. She also shares practical strategies, systems and workflows providers and practices can implement to help navigate through these potential challenges.This episode was supported by educational grant funding from Abbott.Explore the latest in diabetes technology as well as trainings and resources on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsExplore danatech's technology affordability tool: Diabetes Technology Affordability OptionsListen to previous episodes of our Danatech Talks diabetes technology series: https://thehuddle.simplecast.com/episodes/basics-diabetes-technology-for-health-care-professionalshttps://thehuddle.simplecast.com/episodes/understanding-cgms-and-interpreting-data-for-beginners  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 95 of Astonishing Healthcare features six previous guests on the show who share astonishing observations from 2025 and some bold predictions for the New Year! Industry veteran Jeffrey Hogan, our General Counsel and Chief Compliance Officer, Lloyd Fiorini, ERISA law expert Nick Welle, two of our clinical leaders – Sarra Izadi, PharmD, Chief Clinical Officer, and Bonnie Hui-Callahan, PharmD, CDCES, Sr. Director, Clinical Programs, and our Chief Technology Officer and Co-Founder, Ryan Kelly, joined us for this round-robin discussion that's packed with insightful reflections and optimism about the future. We won't ruin it in the show notes, but based on what we saw in 2025: Everyone has finally had enough of the costs and opacity of the U.S. healthcare system – a $70k family premium is truly astonishing It's surprising that, despite the lawsuits, warnings, and reform efforts, the proverbial hammer didn't drop on anyone for not being a good health plan fiduciary The speed and impact of AI have broadly been more positive than expected The rise of cardio-diabesity How GLP-1s helped shift the balance of power in the pharmaceutical supply chain And in 2026, we may see: Employers fight back – they take agency over their plans, and for first movers that started with transitioning to aligned PBMs, it's “game on” for the rest of their health plans The cash price – or acquisition cost – of drugs in the U.S. becomes the baseline – i.e., we finally see a real change in how drugs are priced ICHRAs and other alternative models become more popular Employers look to new clinical programs and models that demonstrate a return on their spending AI become more important for clinical workflows (not decision-making, at least not yet) Pharmaceutical manufacturers find themselves with increasing bargaining power vs. traditional PBMs A new Stanley Cup champion, and a Super Bowl ring for… Related Content Judi Health Policy Pulse: 2025 Regulatory Roundup, the Push for PBM Reform Replay - Unifying Medical and Pharmacy Benefits: The Blueprint for Better Employee Health and Wellness AH094 - How Unified Claims Processing Evolved from Pharmacy: Improving Member Care & Operating Efficiency Health Benefits 101: The Importance of Clinical Programs How to obtain Rx data and what to do with it For more information about Capital Rx and this episode, please visit Judi Health - Insights.

Is ongoing hair loss more than just aging or genetics? More than 35 million men and 21 million women experience hair loss to some degree. Pharmacist and physician liaison, Bryana Gregory, takes a root-cause approach to understanding hair loss and hair regrowth. She explains how factors like hormonal imbalance, nutrient deficiencies, chronic stress, thyroid dysfunction, inflammation, and post-viral immune stress can disrupt the natural hair growth cycle and lead to excessive shedding. Hair loss is often the result of the body prioritizing survival over auxiliary functions like hair growth, especially during periods of prolonged inflammation.   Bryana introduces a proprietary compounded Hair Support Solution designed to address both hair loss and regrowth simultaneously. This topical formulation combines three synergistic ingredients to support circulation, collagen production, and follicle regeneration, and help reactivate dormant hair follicles. Together, these ingredients work locally at the scalp without systemic absorption, supporting healthier follicles and longer growth phases.   The episode also emphasizes the importance of supporting hair health through proper nutrition, adequate protein intake, stress management, and avoiding inflammatory hair products. Bryana explains how consistent topical use, combined with lifestyle awareness, can help restore balance at the follicular level. For those experiencing chronic hair thinning, post-COVID hair loss, or hormone-related shedding, this compounded solution offers a targeted, physician-guided option for addressing hair loss at its source.   Watch now and subscribe to our podcasts at www.HotzePodcast.com.   To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

In this episode, host Suzanne Feeney, PharmD, Senior Director, Pharmacy Solutions at McKesson Health Mart and guest Jaime Montuoro, PharmD, Director of Education & Practice Advancement at McKesson Health Mart, unpack two strategies you can deploy now: PGY1 community-based residencies and pharmacy credentialing. You'll learn how residency trained pharmacists can elevate clinical care in workflow, fuel change and help launch billable services. Then, we get practical on credentialing—why becoming “provider ready” matters and how claiming your team's Pharmacy Profiles credentials streamlines payer opportunities. Jaime shares real-world wins, including how Bryant Family Pharmacy partnered with a resident to implement prescriptive authority programs patients were willing to pay for. If you're ready to move beyond the transaction and build sustainable, community anchored care, this playbook will help you start today. HostSuzanne Feeney, PharmDSr. Director, Pharmacy Solutions McKesson / Health MartGuestJaime Montuoro, PharmDDirector, Education and Practice AdvancementMcKesson / Health MartResourcesTune into Episode 11: Maximizing Operations Through Proactive Workflow Health Mart Pharmacies can access Health Mart University (HMU) for:Health Mart pharmacists to claim their CE credit for weekly GameChangers episodesReferencesLearn more about the Health Mart Postgraduate Year One Community-based Pharmacy Residency Program herePharmacy Profiles is a pharmacy-friendly database that allows pharmacy teams to showcase their training and certifications in one place. If you're a Health Mart pharmacy demonstrate your pharmacy's readiness to receive potential patient care opportunities more quickly by having your pharmacy professionals claim their MYPROFILE. Learn more here: my.pharmacyprofiles.com. Pharmacy Profiles is a Strategic Health Alliance II, Inc., vendor.  The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

On this episode, we discuss tobacco use disorder and describe its clinical impact, common presentations, and underlying neurobiological mechanisms. We evaluate current guidelines and evidence-based treatment strategies for smoking cessation, including pharmacologic and behavioral interventions. We also compare and contrast the efficacy, safety profiles, and appropriate use of nicotine-replacement therapies, prescription pharmacotherapies, behavioral strategies, and long-term patient follow-up in smoking cessation. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

We bring back our prior pharmacology discussion because it's so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!Content:- What are common drugs we use in "triplet regimens"? "quadruple therapy"? - What considerations must we take into account when prescribing commonly used medications in myeloma? - How should we counsel our patients? - What about supportive care?- How and when do we make dose adjustments? - This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not seeWant to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, our guest is Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Dr. Relling earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and was chair ofthe Department of Pharmaceutical Sciences from 2003-2020. She was also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy. Her primary interests are in the treatment and pharmacogenetics of childhood leukemia and in the clinical implementation of pharmacogenetic testing in medicine. Dr. Relling is co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 450 original scientific manuscripts. She was elected to the Institute of Medicine (National Academy of Medicine) in 2009.Topics to discuss:Foundations & Career JourneyYou've had an extraordinary career at St. Jude since joining in 1988. What first drew you to pediatric pharmacology and pharmacogenetics?Your work has helped shape how we treat childhood leukemia. What do you see as the most transformative advancements in this space over your career?Pharmacogenetics & CPICYou co-founded the Clinical Pharmacogenetics Implementation Consortium (CPIC). What was the impetus behind its creation, and how has its mission evolved?What do you see as the biggest barriers to widespread clinical implementation of pharmacogenetic testing today?How do you respond to skepticism about the clinical utility of pharmacogenetic testing in everyday medical practice?Which pharmacogenetic guidelines do you believe have had the most significant clinical impact so far—and why?What advice do you have for institutions that want to start implementing pharmacogenetic testing but don't know where to begin?Implementation in Clinical SettingsAt St. Jude, you helped lead efforts to integrate pharmacogenetic testing into clinical care. What lessons did you learn about operationalizing this work in real-world settings?How important is interdisciplinary collaboration—between pharmacists, physicians, geneticists—in making pharmacogenetic testing work in practice?Can you share an example where pharmacogenetic testing changed the course of treatment for a pediatric patient?Policy, Ethics, and Future VisionWhat policy or regulatory changes would help accelerate the clinical adoption of pharmacogenetic testing?As someone who has contributed extensively to the science, how do you think we should balance data privacy with the need for clinical data sharing in genomics?What are you most excited about in the future of pharmacogenetics? Are there particular therapeutic areas or technologies that you think will drive the next wave of innovation?Legacy & AdviceYou've mentored many rising leaders in the field. What qualities do you think are most important for the next generation of pharmacogenomics researchers and clinicians?With over 450 publications and a career that has changed pediatric pharmacology, what legacy do you hope your work leaves behind?Guest: Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research HospitalHost: Hillary Blackburn, PharmD, MBAwww.hillaryblackburn.comhttps://www.linkedin.com/in/hillary-blackburn-67a92421/  ★ Support this podcast on Patreon ★

Matt and Paul recap top pearls from a recent episode on Anticoagulation for Venous Thromboembolism with Dr. Tara Lech, PharmD. They also answer listener questions and share their picks of the week.  Picks of the week: Paul Recommends: Death Stranding 2: On the Beach (videogame) Matt Recommends: CJ Box novels about Joe Picket

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

In this episode, Kuldip R. Patel, PharmD, FASHP, Senior Associate Chief Pharmacy Officer at Duke University Health System, discusses how pharmacy services are expanding across the continuum to reach more patients and improve outcomes. He shares insights on supply chain resilience, ambulatory and inpatient pharmacy growth, and the technologies shaping the future of pharmacy practice.

We bring back our prior pharmacology discussion because it's so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!Content:- What are common drugs we use in "triplet regimens"? "quadruple therapy"? - What considerations must we take into account when prescribing commonly used medications in myeloma? - How should we counsel our patients? - What about supportive care?- How and when do we make dose adjustments? - This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not seeWant to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, Sterling Elliott, PharmD, BCMTMS, Clinical Pharmacist Lead, Assistant Professor of Orthopaedic Surgery at Northwestern Medicine & Affiliate Faculty Member, Purdue University College of Pharmacy, shares how pharmacists are stepping into expanded leadership roles in ambulatory and procedural care amid rising cost pressures and the shift to value based care. He discusses opioid stewardship in orthopedic surgery, innovative patient education models, and the barriers and opportunities facing pharmacists practicing at the top of their license.

Independent pharmacists are going beyond the counter to provide exceptional services through community partnerships. In this episode of The Counter Talk™ Podcast host Jason Callori speaks with Kristen Glesman, PharmD, Mandilyn Coffman, PharmD and Emily Rohling, PharmD.  These pharmacists share how they're transforming their pharmacies into vital community health destinations by partnering with local businesses and more . Hear from your peers on identifying opportunities, navigating challenges, and fostering a passionate team to drive innovation and growth.   

In this encore episode of 'Relentlessly Seeking Value,' host Stacey Richter revisits an inspiring conversation with Marilyn Bartlett, a CPA who transformed the State of Montana's employee health plan from a $9 million deficit to a $112 million surplus within three years.  Known for her fiscal discipline and patient-first approach, Marilyn shares her strategic steps, from identifying waste in the system and securing quick wins to negotiating better deals with hospitals and ensuring long-term success. She emphasizes the importance of assembling a strong team, maintaining transparency, and staying focused on the ultimate goal of creating real health value. This episode is a must-listen for anyone looking to drive meaningful change in the healthcare industry. === LINKS ===

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing medicine — but at what cost? In this episode of The Exam Room Podcast, host Chuck Carroll sits down with Ben Urich, PharmD, PhD, to break down the real-world data behind the GLP-1 explosion. You'll learn: - How many people are actually using GLP-1 drugs - Why most users stop — and why that's starting to change - The true cost of GLP-1 medications to employers and health plans - Common and serious side effects to be aware of - Why GLP-1s are now being studied for Alzheimer's disease and addiction - What the future holds as more than 30 new drugs enter the pipeline This is a must-watch conversation for anyone considering GLP-1 medications, currently using Ozempic or Wegovy, or wondering where modern weight-loss medicine is headed next.